On May 24, 2024, the company announced that it has extended its plan duration till November 29, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.71 AUD | +1.51% |
|
+2.17% | -23.41% |
06-03 | Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland | MT |
05-24 | Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.41% | 255M | |
+20.76% | 43.77B | |
+28.00% | 22.83B | |
+20.25% | 15.56B | |
+18.82% | 14.34B | |
+55.83% | 12.96B | |
-0.05% | 6.79B | |
-12.70% | 6.41B | |
-8.87% | 5.73B | |
+14.65% | 5.69B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Group Limited's Equity Buyback Plan Extended till November 29, 2024.